Wednesday, 20 May 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 20 May 2026
News

Obesity drugs now gold standard

 Posted 20 May 2026 PM

The use of GLP-1s is a key pillar in the Heart Foundation’s new guidance for treating obesity and reducing the risk of heart attack or stroke.

Australia’s first Clinical Consensus Statement on Obesity and Cardiovascular disease (CVD), launched in collaboration with the World Heart Federation in Geneva this week, is intended to serve as the gold standard of overweight and obesity management for healthcare professionals whose patients have heart disease or a high risk of developing it.

To see the whole article, please login

Popular

World's Most Innovative Pharma is...
Inside Aussie Med Affairs salaries
Aussie GM steps up to regional role
Drugs battle for US$2.7B market
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home